AngioDynamics, Inc. (NASDAQ: ANGO) has appointed Eric Honroth as President and Chief Executive Officer effective November 2, replacing Jim Clemmer after a ten-year tenure that reshaped the medical technology company’s portfolio and operating model. Honroth will also join the board, while Clemmer will leave the board and remain available in a consulting capacity to support the transition.
The succession arrives at an important point in AngioDynamics’ transformation. First-quarter fiscal 2027 net sales increased 6.9% to $80.9 million, while Med Tech sales grew 13.2% to $39.9 million. Adjusted EBITDA rose to $5 million from $2.2 million a year earlier, extending the company’s run of positive adjusted EBITDA.
Yet the market response was severe. AngioDynamics shares fell 20.86% on October 8, closing at $11.23, before recovering 2.58% to $11.52 on October 9. The magnitude of the decline makes Honroth’s arrival more consequential because he will inherit not only improving operating metrics but also an investor base demanding greater confidence in the company’s future earnings trajectory.
Why did AngioDynamics choose Eric Honroth as its next CEO?
The board said its search prioritised medical technology experience, commercial execution and operating discipline. Honroth brings more than two decades of experience across cardiovascular, endovascular, urology and oncology markets, making his background closely aligned with the products AngioDynamics is attempting to scale.
He most recently served as Global President, Life Science at Getinge and previously led Getinge’s approximately $1.2 billion North American business. Earlier roles included positions with Abbott Vascular, Becton Dickinson, CareFusion and Boston Scientific.
That background suggests the board is looking for a commercially oriented operator rather than a leader primarily tasked with another portfolio restructuring. AngioDynamics has already spent years sharpening its strategic focus under Clemmer. The next challenge is turning its portfolio of faster-growing medical technologies into sustainable revenue expansion and stronger profitability.
The company’s own language around the appointment emphasises that transition. The board has highlighted med-tech momentum, the absence of outstanding debt and an operational transformation that is already generating results.
Honroth is therefore inheriting a platform that is more focused than the one Clemmer began leading a decade ago, but the market is also demanding more from it.
Which AngioDynamics products are driving the current growth?
The strongest performance is coming from the company’s Med Tech portfolio. Auryon generated first-quarter sales of $18.9 million, up 14.7% year over year, while NanoKnife sales rose 29% to $8.3 million.
Mechanical thrombectomy sales reached $12 million, increasing 6.7%. Within that category, AlphaVac sales increased 37.4%, although AngioVac revenue declined 5.9% from a year earlier while improving sequentially.
These numbers show why the Chief Executive Officer transition is being framed around commercial acceleration. AngioDynamics is no longer relying on one product to demonstrate growth. Multiple technology platforms are contributing, giving management several opportunities to expand utilisation and physician adoption.
NanoKnife also carries potential beyond its current oncology applications. AngioDynamics received United States Food and Drug Administration approval for an investigational device exemption covering the RELIEF feasibility study evaluating NanoKnife irreversible electroporation for benign prostatic hyperplasia.
The study is designed to enrol 40 patients at up to five United States sites. While that programme remains developmental and should not be treated as established commercial revenue, it illustrates how the company is attempting to widen the addressable market around technologies already inside its portfolio.
Why did AngioDynamics shares fall so sharply on October 8?
The timing creates a temptation to attribute the 20.86% share-price decline either to the Chief Executive Officer announcement or to a single number inside the earnings report. The publicly available information does not support such a simple conclusion.
AngioDynamics delivered revenue growth, stronger adjusted EBITDA and improved GAAP losses while reiterating its fiscal 2027 guidance. At the same time, investors may have been assessing the pace of future margin improvement, second-half gross-margin expectations, continued adjusted losses and the leadership transition simultaneously.
The first-quarter GAAP gross margin reached 59.4%, up substantially from the prior year, although the result benefited from tariff refunds. Excluding that benefit, gross margin would have been 57.8%, and management has already indicated that second-half fiscal 2027 gross margin is expected to be below first-half levels.
AngioDynamics also remains loss-making under GAAP. The first-quarter net loss narrowed to $7.1 million from $10.9 million, while adjusted net loss improved to $1.8 million from $4.2 million.
Those figures represent genuine progress without yet establishing durable bottom-line profitability. Investors valuing AngioDynamics primarily as a growth med-tech platform may consequently be sensitive to any signal that the pathway to higher margins could take longer than hoped.
What financial targets will Eric Honroth inherit?
AngioDynamics reaffirmed fiscal 2027 net sales guidance of $336 million to $341 million. The company expects Med Tech sales growth of between 12% and 15%, while Med Device revenue is expected to remain approximately flat.
Full-year gross margin is forecast at 54% to 55%, with adjusted EBITDA expected between $13 million and $16 million. Adjusted earnings per share are still projected to be negative, within a range of approximately $0.24 to $0.29 per share loss.
That guidance explains the opportunity and the challenge. The Med Tech business is producing double-digit growth and the company is generating positive adjusted EBITDA, but revenue mix and manufacturing economics still need to improve before stronger operating momentum becomes sustained earnings.
Honroth’s commercial background could prove useful here. Growing innovative medical technologies involves more than obtaining regulatory clearances. Companies need physician adoption, hospital purchasing support, clinical evidence, reimbursement pathways and disciplined sales execution.
The new Chief Executive Officer will therefore be judged on how effectively AngioDynamics converts clinical and technological differentiation into recurring commercial demand.
Is the CEO transition a strategic reset or continuation of Jim Clemmer’s transformation?
The evidence points more strongly toward continuation than reversal. Clemmer spent a decade narrowing the company’s focus, improving capabilities and positioning AngioDynamics around growth-oriented technologies. He will remain as an adviser during the handover, reducing the risk of an abrupt strategic break.
Honroth appears to have been selected to accelerate what has already been built. The emphasis on commercial execution, revenue growth and margin expansion suggests the board believes the portfolio is sufficiently focused and now needs stronger monetisation.
That does not mean organisational changes should be ruled out. New Chief Executive Officers frequently reassess reporting structures, investment priorities and leadership teams after taking control, particularly when shareholders are demanding better returns.
However, AngioDynamics does not appear to be recruiting Honroth to dismantle the strategy. It is asking him to make the strategy produce more financial value.
The October 8 share-price decline gives that assignment greater urgency. Improving product growth alone may no longer satisfy investors if it is not accompanied by convincing evidence of expanding margins and a clearer path to earnings.
For AngioDynamics employees and shareholders, November 2 therefore marks more than a ceremonial leadership handover. It begins the next phase of a decade-long transformation in which success will increasingly be measured by whether the company’s expanding med-tech portfolio can translate growth into durable profitability.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
